Clinical Trial Update: Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) [Phase 2]

View source ↗

Summary

Phase 2 trial completed evaluating fostamatinib disodium (R935788) for adult patients with refractory immune thrombocytopenia (ITP). Results were posted in 2014…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Fostamatinib disodium (fostamatinib disodium)

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Purpura, Thrombocytopenic, Idiopathic | Phase 2 | Status: COMPLETED | Results posted: 2014-08-13